By Dr Lisa Mary Raven

Journal articles

Raven LM, 2024, 'Understanding the cardiovascular benefits of glucagon-like peptide-1 (GLP-1) receptor agonists.', Trends Cardiovasc Med, http://dx.doi.org/10.1016/j.tcm.2024.03.007

Raven LM; Brown C; Greenfield JR, 2024, 'Considerations of delayed gastric emptying with peri-operative use of glucagon-like peptide-1 receptor agonists', Medical Journal of Australia, 220, pp. 14 - 16, http://dx.doi.org/10.5694/mja2.52170

Kuang W; Raven LM; Muir CA, 2024, 'Early post-transplant hyperglycemia and post-transplant diabetes mellitus following heart transplantation', Expert Review of Endocrinology and Metabolism, 19, pp. 129 - 140, http://dx.doi.org/10.1080/17446651.2024.2307011

Raven LM; Goodall L; Center JR; Muir CA, 2024, 'Teriparatide as Treatment for Severe Osteoporosis in Lung Transplant Recipients.', JCEM Case Rep, 2, pp. luae026, http://dx.doi.org/10.1210/jcemcr/luae026

Raven LM; Stoita A; Feller RB; Brown C; Greenfield JR, 2023, 'Delayed Gastric Emptying with Perioperative Use of Glucagon-like Peptide-1 Receptor Agonists', American Journal of Medicine, 136, pp. e233 - e234, http://dx.doi.org/10.1016/j.amjmed.2023.07.016

Chavali S; Barua S; Adji A; Robson D; Raven LM; Greenfield JR; Eckford H; Macdonald PS; Hayward CS; Muthiah K, 2023, 'Safety and tolerability of sodium-glucose cotransporter-2 inhibitors in bridge-to-transplant patients supported with centrifugal-flow left ventricular assist devices', International Journal of Cardiology, 391, http://dx.doi.org/10.1016/j.ijcard.2023.131259

Hayes AG; Raven LM; Viardot A; Kotlyar E; Greenfield JR, 2023, 'SGLT2 Inhibitor-Induced Ketoacidosis in a Patient Without Diabetes', Diabetes Care, 47, pp. e4 - e5, http://dx.doi.org/10.2337/dc23-1903

Raven LM; Muir CA; Greenfield JR, 2023, 'Sodium glucose cotransporter 2 inhibitor-induced ketoacidosis is unlikely in patients without diabetes', Medical Journal of Australia, 219, pp. 293 - 294, http://dx.doi.org/10.5694/mja2.52067

Raven LM; Muir CA; Pouliopoulos J; Hayward CS; Macdonald PS; Greenfield JR; Jabbour A, 2023, 'Metabolic Sequelae of Everolimus Treatment After Cardiac Transplant: A Hypothesis-Generating Study', Heart Lung and Circulation, 32, pp. 1076 - 1079, http://dx.doi.org/10.1016/j.hlc.2023.05.014

Raven LM; Muir CA; Macdonald PS; Hayward CS; Jabbour A; Greenfield JR, 2023, 'Diabetes medication following heart transplantation: a focus on novel cardioprotective therapies—a joint review from endocrinologists and cardiologists', Acta Diabetologica, 60, pp. 471 - 480, http://dx.doi.org/10.1007/s00592-022-02018-3

Chavali S; Barua S; Adjii A; Robson D; Raven L; Greenfield J; Parvar S; MacDonald P; Hayward C; Muthiah K, 2023, 'Safety and Tolerability of Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Patients Supported with Left Ventricular Assist Devices', JOURNAL OF HEART AND LUNG TRANSPLANTATION, 42, pp. S450 - S451, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000992480601267&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Raven LM; Muir CA; Kessler Iglesias C; Bart NK; Muthiah K; Kotlyar E; Macdonald P; Hayward CS; Jabbour A; Greenfield JR, 2023, 'Sodium glucose co-transporter 2 inhibition with empagliflozin on metabolic, cardiac and renal outcomes in recent cardiac transplant recipients (EMPA-HTx): Protocol for a randomised controlled trial', BMJ Open, 13, http://dx.doi.org/10.1136/bmjopen-2022-069641

Raven LM; Greenfield JR; Muir CA, 2023, 'Glucagon-like Peptide-1 Receptor Agonist Treatment With Semaglutide in Type 1 Diabetes.', JCEM Case Rep, 1, pp. luac017, http://dx.doi.org/10.1210/jcemcr/luac017

Raven LM; Morris P; Greenfield JR, 2022, 'Hyperglycaemia induced by gamma-butyrolactone', Diabetic Medicine, 39, http://dx.doi.org/10.1111/dme.14850

Raven LM; Chen R, 2022, 'New medications for diabetes When to use what?', Medicine Today, 23, pp. 47 - 51

Raven LM; Mccormack AI; Greenfield JR, 2022, 'Letter to the Editor From Raven et al: "Three Cases of Subacute Thyroiditis Following SARS-CoV-2 Vaccine"', Journal of Clinical Endocrinology and Metabolism, 107, pp. E1767 - E1768, http://dx.doi.org/10.1210/clinem/dgab822

Raven LM; McCormack AI, 2022, 'Female Representation: Australian Diabetes and Endocrinology Societies', Frontiers in Endocrinology, 13, http://dx.doi.org/10.3389/fendo.2022.842909

Raven LM; Muir CA, 2021, 'Something to chew on: an unusual case of hyponatraemia secondary to chewing gum ingestion', Internal Medicine Journal, 51, pp. 1748 - 1749, http://dx.doi.org/10.1111/imj.15521

Raven LM; Guttman-Jones M; Muir CA, 2021, 'Hyperprolactinemia and association with prolactinoma in transwomen receiving gender affirming hormone treatment', Endocrine, 72, pp. 524 - 528, http://dx.doi.org/10.1007/s12020-020-02563-3

Crowhurst TD; Floridis J; Raven LM, 2012, 'Medical student views about changes to internships in South Australia', Medical Journal of Australia, 197, pp. 90 - 91, http://dx.doi.org/10.5694/mja12.10278

Back to profile page